Recent studies have evaluated the potential utility of recombinant TIMP3 in cardiovascular diseases [53] and engineered TIMP3 molecules with an additional glycosylation site led to improved expression and cardiac function in a rodent model of myocardial infarction [54]. The gene discussed is TIMP3; the disease is myocardial infarction.